To reach the next value inflection
LicenseRx asset brief
Novel Compounds for Sensitization of Cancer Cells to EGFR Inhibitors
Probability of Success
73% · grade B · Medium data confidence
Model PoS 73% (grade B, medium data confidence). Strongest signals: Data maturity, Modality feasibility. Biggest drag: Translational evidence.
Data maturity (22%)
89
Commercial-Ready; human data.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
82
Small molecule -- well-trodden regulatory and CMC path.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
60
Crowded oncology field.
Translational evidence (12%)
54
Public evidence mentions: human.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →